4 drug(s) with this reaction
4,228 total reports
Application Site Erythema has been reported as an adverse reaction across 4 drug(s) manufactured by Haleon Us Holdings Llc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 4,228 adverse event reports mention application site erythema in connection with Haleon Us Holdings Llc products.
This page provides a breakdown of which Haleon Us Holdings Llc drugs are most commonly associated with application site erythema, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Haleon Us Holdings Llc drugs have application site erythema listed in their FDA adverse event reports, sorted by report count:
In addition to application site erythema, the following adverse reactions have been reported across Haleon Us Holdings Llc's drug portfolio:
4 drug(s) manufactured by Haleon Us Holdings Llc have application site erythema listed in their FDA adverse event reports: NICOTINE, NICOTINE POLACRILEX, GLYCERIN, LIDOCAINE, DOCOSANOL.
There are a combined 4,228 reports of application site erythema across 4 Haleon Us Holdings Llc drug(s) in the FDA adverse event database.